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LIST OF ABBREVIATIONS 
AR Atrophic Rhinitis 
PAR Primary Atrophic Rhinitis 
SAR Secondary Atrophic Rhinitis 
IT Inferior Turbinate 
MT Middle Turbinate 
MM Medial Maxillectomy 
RR Relative Risk 
CI 95% Confidence Interval 
IP Incidence Proportion 
5 
ABSTRACT 
INCIDENCE OF ATROPHIC RHINITIS AFTER ENDOSCOPIC 
SINONASAL SURGERY: A RETROSPECTIVE REVIEW 
BACKGROUND:
Sinonasal tumours have been resected endoscopically at Groote Schuur 
Hospital Cape Town South Africa since 2003. Surgery, although seen as 
minimally invasive because no external incisions are visible, is often very 
aggressive and destructive to the nasal structures. The removal of the 
nasal turbinates has always been seen as sacrilege due to the risk of 
developing atrophic rhinitis. If the theory regarding developing atrophic 
rhinitis after a simple turbinectomy stands true, one would expect a high 
incidence of atrophic rhinitis after radical resection of the sinonasal 
structures. This has not been our experience. 
METHODS: 
The study population includes a retrospective case review of all patients that 
had endoscopic sinonasal tumour resection by the same surgeon between 
2006 and 2010. All patients were assessed for symptoms and signs 
suggestive of atrophic rhinitis up to two years post resection.
RESULTS:
51 patients (34M: 17F) were included in the study. Patients with residual or 
recurrent tumour (n=19) and patients who had received adjuvant 
radiotherapy (n=17) had a statistically significant chance of developing 
symptoms and signs suggestive of atrophic rhinitis over time. Variables such 
as age, gender, extent of surgery, bilateral disease, benign or malignant 
tumour, were not statistically significant in the development of symptoms and 
signs suggestive of atrophic rhinitis over time. 
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CONCLUSIONS:
Atrophic rhinitis is not more common in patients who undergo endoscopic 
sinonasal surgery without adjuvant therapy. However, patients with residual 
tumour (after debulking surgery) or recurrent tumour and those who had 
received adjuvant radiotherapy had a statistically significant chance of 
developing symptoms and signs suggestive of atrophic rhinitis over time.
Keywords: atrophic rhinitis, endoscopic resection, turbinectomy, medial 
maxillectomy, sinonasal tumours.
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Atrophic Rhinitis (AR) is a chronic debilitating disease of the nasal passages 
that is characterized by progressive atrophy of the nasal mucosa, nasal 
crusting, fetor (foul smelling nasal discharge) and enlargement of the nasal 
space with paradoxical subjective nasal congestion. Patients with AR may 
also complain of a disordered sense of smell, but complete anosmia is rare 
until late in the disease process.1 Much confusion exists in the literature 
regarding the diagnosis, aetiologic factors, and treatment of AR. Different 
terminologies have been used interchangeably in the literature (atrophic 
rhinitis, rhinitis sicca/dry nose, ozaena and even empty nose syndrome2, 3) 
and this has made investigation of the causes and treatment of the condition 
difficult.  
Since the middle of the century, various authors have divided AR into two 
separate entities. Primary atrophic rhinitis (PAR) is of spontaneous onset, 
progresses slowly and has an unspecified aetiology. Secondary atrophic 
rhinitis (SAR) develops after chronic rhinosinusitis, chronic granulomatous 
disease, excessively aggressive surgery in inflammatory/infectious nasal and 
sinus surgery, nasal trauma or irradiation. PAR may represent early ozaena 
before the submucosal destructive processes brought on by inheritable or 
infections causes have progressed to their end state.4 SAR is much more 
commonly encountered, although it is no more completely understood. 
Characteristic findings in both forms include nasal crusting, enlarged nasal 
cavities, resorption of the turbinates, mucosal atrophy, and paradoxical nasal 
congestion.5 The distinction between the two diseases lie in the aetiology. 
Frequent attention is given to SAR because of numerous debates that have 
addressed the association between atrophic rhinitis and modified or total 
reductive turbinate surgery.6-15 If the theory regarding developing atrophic 
rhinitis after turbinectomy stands true, one would expect all patients 
undergoing radical resection of the nasal structures to develop atrophic 
rhinitis. This has not been the case in our experience.  
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PURPOSE OF THE STUDY 
We hypothesise that atrophic rhinitis is not common after extensive 
endoscopic sinonasal surgery. The primary aim of the study is to determine 
the incidence of developing signs and symptoms suggestive of atrophic 
rhinitis after endoscopic sinonasal surgery. We challenge the current 
literature that suggest a simple turbinectomy can lead to atrophic rhinitis and 
postulate that an underlying systemic disorder or other mechanism is 
required to develop this condition.  
METHODOLOGY 
STUDY DESIGN 
A retrospective case review includes all patients who had sinonasal tumours 
endoscopically resected by the same surgeon from 2006 – 2010 at Groote 
Schuur Hospital, Cape Town South Africa. All patients included in the study 
were given standard post-operative instructions and were followed up for at 
least two years after surgery.  They were assessed for symptoms and signs 
suggestive of atrophic rhinitis at each visit. 
The same surgeon assessed all patients pre-operatively. A thorough history 
and examination, including nasendoscopy was performed prior to each 
surgery. Special investigations included a histological diagnosis and imaging 
(CT and/or MRI scans of the sinuses). Tumour location and extent of surgery 
was documented and patients followed up as per routine. All patients were 
given instructions on post-operative care in terms of nasal douching and 
nasal hygiene. Post-operative follow-up was done at the following intervals: 2 
weeks, 6 weeks, 3 months, 6 months , 12 months, 18 months and 24 months 
or sooner at the discretion of the surgeon. At each visit the patient was 
assessed for symptoms and signs suggestive of atrophic rhinitis. 
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CHARACTERISTICS OF THE STUDY POPULATION 
All adult patients at Groote Schuur hospital who were assessed and 
diagnosed with a sinonasal tumour (benign or malignant) and proceeded to 
have an endoscopic excision (curative or palliative) by the same surgeon, 
were included in the study. A time frame between 2006 and 2010 was 
chosen, allowing for a minimum 2 - year follow-up. The study is aimed at 
recording symptoms and signs suggestive of atrophic rhinitis and to assess 
the presence / absence of a ‘cause – effect’ relationship. 
RESEARCH PROCEDURES AND DATA COLLECTION METHODS 
The primary investigator will record data in relation to certain patient 
demographics, type and extent of tumour, procedure performed and follow- 
up symptoms and signs at the post-operative visits. 
Post-operative care is performed according to standard existing management 
protocols which includes nasal douching and nasal hygiene. Follow-up is 
performed at 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 18 months 
and 24 months. At each visit the patient will be assessed for symptoms and 
signs suggestive of atrophic rhinitis.  
DATA SAFETY AND MONITORING 
The primary investigator will act as study co-ordinator and will be responsible 
for the safety of the collected data. 
DATA ANALYSIS 
Statistical data analysis will be performed using a statistical program and 
interpreted with the help of a statistician to evaluate our hypothesis. 
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RESULTS / OUTCOME MEASURES 
The incidence of atrophic rhinitis in post-operative patients will be assessed. 
Patient demographics and other factors which may influence the 
development of the disease process will be looked at. Post- operative follow 
up of at least 2 years will be looked at.  
PROJECTED COSTS 
None 
RISKS TO PATIENT 
None 
PRIVACY AND CONFIDENTIALITY
The primary investigator will act as study coordinator and will be responsible 
for the safety of the collected data. Data collected and recorded on data 
sheets will be recorded electronically using Microsoft Excel. All materials will 
be kept in a locked room within the ENT ward.  A hospital number will be 
recorded as a patient identifier within the raw data in order to permit 
verification of information at later stages during analysis. 
Patient-specific information will neither be required nor included during data 
analysis. 
WHAT HAPPENS AT THE END OF THE STUDY? 
Should the hypothesis be proven, the investigators plan to submit findings of 
the study to an international scientific journal for publication. 
No proprietary interests to declare.  
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PART B: STRUCTURED LITERATURE REVIEW 
INCIDENCE OF ATROPHIC RHINITIS AFTER ENDOSCOPIC SINONASAL 
TUMOUR RESECTION  
Introduction 
Over the past decade, there has been a natural evolution in the capabilities 
of endoscopic sinus surgeons. Advances in endoscopic instrumentation, the 
availability of intraoperative imaging and increased experience with 
endoscopic repair of even large skull base defects, have led to a shift from 
open surgery to the endoscopic resection of advanced sinonasal tumours. 
Many endoscopic surgeons have continued to fine-tune their skills and 
improve their knowledge of the complex orbital and skull base anatomy. 
Initially advocated for obstructive inflammatory disease, endoscopic 
approaches are now being used increasingly for the definitive treatment of 
nasal and paranasal sinus tumours, previously resected through more 
traditional (transfacial or craniofacial) approaches. Endoscopic management 
of benign and malignant lesions, reflects a fundamental change from the 
more traditional therapeutic concepts and modalities.1-3 
Sinonasal tumours have been resected endoscopically at Groote Schuur 
Hospital in Cape Town since 2003. Almost all benign and intermediate 
tumours are removed endoscopically as well as malignant tumours amenable 
to this minimally invasive surgical approach. Surgery, although seen as 
minimally invasive because no external incisions are visible, is often very 
aggressive and destructive to the nasal structures. Current literature 
suggests that one of the causes of secondary atrophic rhinitis is 
overaggressive nasal surgery, particularly turbinate surgery.6-9 If the theory 
regarding developing atrophic rhinitis after a simple turbinectomy stands true, 
one would expect all patients undergoing radical resection of the nasal 
structures to develop atrophic rhinitis.  
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Objectives and Search Strategy 
The objective of the literature review is firstly to review the existing evidence 
relating to the aetiology of atrophic rhinitis and more specifically the role of 
nasal surgery, particularly endoscopic nasal surgery and the development of 
atrophic rhinitis. Existing levels of evidence and research methods employed 
will also be examined. Deficiencies in current published knowledge and scope 
for further research will be identified. 
A systematic search for relevant literature, not restricted to English literature 
only, was conducted using Medline® and PubMed® systems. The following 
key words were used: endoscopic nasal resection, endoscopic medial 
maxillectomy, atrophic rhinitis, complications of turbinate surgery. No relevant 
review was found in the Cochrane database, and to our knowledge, no studies 
published on the development of atrophic rhinitis after endoscopic sinonasal 
tumour resection. 
Studies have examined the likely aetiology and diagnosis of secondary 
atrophic rhinitis (SAR). The largest study to date by Moore and colleagues 
(Mayo Clinic Otorhinolaryngology) published in 2001, identified 242 cases of 
atrophic rhinitis of which 197 cases were SAR. According to this study, 
24%(47) were due to complete removal of the lower and middle turbinates, 
56%(110) were due to partial removal of the lower and/or middle nasal 
turbinates, 10%(20) to endonasal sinus surgery without turbinectomy, 6%(12) 
tumour removal with partial maxillectomy, 2%(4) due to sinonasal irradiation 
and 2%(4) due to nasal trauma/granulomatous disease.4  
Some of the older studies done between 1987 – 1999, have authors 
reporting 15 – 89% of their own patients experiencing post – operative 
atrophic rhinitis symptoms after nasal tissue removal particularly in the form 
of turbinectomy. A retrospective study by Moore and colleagues published in 
1985 (University of Nabraska) identified 18 patients who had undergone total 
inferior turbinectomies for nasal obstruction (1977 – 1982). They were 
followed up for 3 to 5 years and 16 of 18(89%) developed symptoms and 
signs of atrophic rhinitis.5  
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Warwick – Brown and colleagues published another retrospective study in 
1987 where 24 out of 207 patients with nasal obstruction were found to have 
undergone partial inferior turbinectomy (Royal Berkshire Hospital, Reading 
UK). Follow up period was 16 years and 18 of 24(75%) developed atrophic 
rhinitis.6 In 1993 a publication by Salam and colleagues (Hull Royal Infirmary, 
Hull) showed in a prospective trial of 25 patients, that total inferior 
turbinectomy resulted in 4 of 25(16%) developing atrophic rhinitis after a 6 
month follow up period.7 Another prospective trial published in 1995 by 
Oburra (Aga Khan Hospital, Nairobi) revealed 5 of 34(15%) patients who had 
bilateral total inferior turbinectomies developed atrophic rhinitis.8 The follow 
up period was not stated in this study. One further prospective study 
published in 1999 by Passali and colleagues (Siena Medical School, Siena, 
Italy) confirmed atrophic rhinitis in 10 of 45(22%) patients who had 
undergone total inferior turbinectomy  and followed up for 4 years.9  
Other authors report that they have never encountered a case of atrophic 
rhinitis after total removal of the inferior turbinates. Martinez and colleagues 
(Nebraska University – Otorhinolaryngology), in 1983, found 29 patients who 
underwent total inferior turbinectomy for nasal obstruction. This was a 
prospective study and patients were followed for 2 – 60 months.10 Only 1 
patient developed excessive dryness but no atrophy. Odetoyinbo in 1987 
(Department of Surgery – Nigeria) reported that none of their 39 patients who 
underwent total inferior turbinectomy had developed atrophic rhinitis after a 2 
year follow up. This too was a prospective study.11 A retrospective study 
done by Courtiss and colleagues, (Division of Plastic surgery, Harvard 
Medical School) published in 1989, showed a 10-year follow up of patients 
who had total inferior turbinectomy with none developing symptoms of 
atrophic rhinitis.12 This study involved 25 patients age range from 24 to 74 
years (mean 39 years). A retrospective study published in 1989 by Ophir, 
(Kaplan Hospital – Israel) showed 38 patients who also underwent total 
inferior turbinectomy for nasal obstruction. There were no signs or symptoms 
of atrophic rhinitis postoperatively and the follow up was from 1 to 7 years.13  
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The first prospective study involving resection of the middle turbinate for 
nasal obstruction was published in 1995 by Cook and colleagues (University 
of Missouri School of Medicine). This study looked at the effect of partial 
middle turbinectomy on nasal airflow and resistance. Thirty-one patients 
were included in the study and were followed up for 3 to 10 months post – 
operatively. No patients developed atrophic rhinitis and nasal function was 
enhanced.14 In 2000 Talmon and collegues (Western Gallilee Hospital – 
Israel) reported on 357 patients who underwent total inferior turbinectomy. 
This was a prospective study and patients were followed up for 6 years. No 
patient developed atrophic rhinitis.15 They also commented that even though 
the climate was hot, dry and dusty, no patients developed excessive dryness 
or atrophy.  
Searching for studies reporting atrophic rhinitis as a result of endoscopic 
sinonasal tumour surgery, delivered no results. There are reports on the 
endoscopic management of sinonasal inverted papillomas but no studies 
mention atrophic rhinitis as a complication of the surgery. The studies were 
mainly concerned with tumour recurrence rates.3 
Two studies published in 2005 and 2008 respectively, compared endoscopic 
and open approaches for sinonasal tumour (benign and malignant) resection. 
Again no mention is made of atrophic rhinitis as a postoperative 
complication, with the main focus again being recurrence rates.1, 2 
Published literature evaluating the cause – effect relationship of atrophic 
rhinitis as a result of nasal surgery is not clear. Also the incidence of atrophic 
rhinitis after endoscopic sinonasal tumour resection cannot be identified by 
an extensive literature review. This represents a significant gap both in the 
existing literature and in evidenced-based practice.  
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To summarize, the literature is not clear with regards to nasal surgery as a 
possible causative factor in the development of atrophic rhinitis. No reports 
could be found on atrophic rhinitis as a result of endoscopic sinonasal tumour 
resection. This generates an interesting research question. Would the 
endoscopic resection of tumours lead to the development of atrophic rhinitis 
in patients where the normal nasal structures (such as the turbinates and 
septum) have been sacrificed?  
The aim of the study is  to review all our endoscopic sinonasal tumour 
resection cases done at Groote Schuur hospital, Cape Town South Africa, by 
the same surgeon between 2006-2010 and assess the incidence of atrophic 
rhinitis as a consequence/complication of this surgery.  
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Sinonasal tumours have been resected endoscopically at Groote Schuur 
Hospital in Cape Town South Africa since 2003. Surgery, although seen as 
minimally invasive because no external incisions are visible, is often very 
aggressive and destructive to the nasal structures. The removal of 
nasal turbinates have always been seen as sacrilege due to the risk of 
developing atrophic rhinitis. If the theory regarding developing atrophic 
rhinitis after a simple turbinectomy stands true, one would expect all patients 
undergoing radical resection of the nasal structures to develop atrophic 
rhinitis. This has not been our experience. 
METHODS:
This restrospective case review includes all patients with both benign and 
malignant sinonasal tumours that have been endoscopically resected by the 
same surgeon from 2006 – 2010 at Groote Schuur Hospital, Cape Town 
South Africa.  We recorded the incidence of post – operative atrophic rhinitis 
over a 2-year follow-up period. 
RESULTS:
51 patients (34M: 17F) were included in the study. Patients with residual or 
recurrent tumour (n=19) and patients who had received adjuvant 
radiotherapy (n=17) had a statistically significant chance of developing 
symptoms and signs suggestive of atrophic rhinitis over time. Variables such 
as age, gender, extent of surgery, bilateral disease, benign/malignant tumour 
were not statistically significant in the development of symptoms and signs 
suggestive of atrophic rhinitis over time.  
CONCLUSIONS:
In our series, atrophic rhinitis is not more common in patients who have had 
extensive endoscopic sinonasal tumour resection (with curative intent) 
without adjuvant radiotherapy. Factors that did influence the development of 
atrophic rhinitis were residual/recurrent disease and adjuvant radiotherapy. 
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INTRODUCTION 
Atrophic Rhinitis (AR) is a chronic debilitating disease of the nasal passages 
that is characterized by progressive atrophy of the nasal mucosa, nasal 
crusting, fetor (foul smelling nasal discharge) and enlargement of the nasal 
space with paradoxical subjective nasal congestion. Patients with AR may 
also complain of a disordered sense of smell, but complete anosmia is rare 
until late in the disease process.1 Much confusion exists in the literature 
regarding the diagnosis, aetiologic factors, and treatment of AR. Different 
terminologies have been used interchangeably in the literature (atrophic 
rhinitis, rhinitis sicca/dry nose, ozaena and even empty nose syndrome2, 3) 
and this has made investigation of the causes and treatment of the condition 
difficult.  
Since the middle of the century, various authors have divided AR into two 
separate entities. Primary atrophic rhinitis (PAR) is of spontaneous onset, 
progresses slowly and has an unspecified aetiology. Secondary atrophic 
rhinitis (SAR) develops after chronic rhinosinusitis, chronic granulomatous 
disease, excessively aggressive surgery in inflammatory/infectious nasal and 
sinus surgery, nasal trauma or irradiation. PAR may represent early ozaena 
before the submucosal destructive processes brought on by inheritable or 
infections causes have progressed to their end state.4 SAR is much more 
commonly encountered, although it is no more completely understood. 
Characteristic findings in both forms include nasal crusting, enlarged nasal 
cavities, resorption of the turbinates, mucosal atrophy, and paradoxical nasal 
congestion.5 The distinction between the two diseases lie in the aetiology. 
Frequent attention is given to SAR because of numerous debates that have 
addressed the association between atrophic rhinitis and modified or total 
reductive turbinate surgery.6-15 If the theory regarding developing atrophic 
rhinitis after turbinectomy stands true, one would expect all patients 
undergoing radical resection of the nasal structures to develop atrophic 
rhinitis. This has not been the case in our experience.  
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MATERIALS AND METHODS 
Study population 
All patients with sinonasal tumours (benign or malignant) who had 
endoscopic resection by the same surgeon at Groote Schuur Hospital, over a 
five year period (2006-2010) were eligible for inclusion. The patients required 
follow-up for at least two years post op.  
Study Design 
A retrospective case review includes all patients who had sinonasal tumours 
endoscopically resected by the same surgeon from 2006 – 2010 at Groote 
Schuur Hospital, Cape Town South Africa. All patients included in the study 
were given standard post-operative instructions and were followed up for at 
least two years after surgery.  They were assessed for symptoms and signs 
suggestive of atrophic rhinitis at each visit. 
The same surgeon assessed all patients pre-operatively. A thorough history 
and examination, including nasendoscopy was performed prior to each 
surgery. Special investigations included a histological diagnosis and imaging 
(CT and/or MRI scans of the sinuses). Tumour location and extent of surgery 
was documented and patients followed up as per routine. All patients were 
given instructions on post-operative care in terms of nasal douching and 
nasal hygiene. Post-operative follow-up was done at the following intervals: 2 
weeks, 6 weeks, 3 months, 6 months , 12 months, 18 months and 24 months 
or sooner at the discretion of the surgeon. At each visit the patient was 
assessed for symptoms and signs suggestive of atrophic rhinitis. 
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Statistical analysis 
Incidence proportions, mean and median values were calculated for all 
patient characteristics, as appropriate. Relative ratios, p-values and 95% 
confidence intervals were used to estimate the relative risk of developing the 
outcome of interest with respect to various categorical predictors by 
generalized linear regression models at time 12 weeks. The statistical 
significance of the association between outcome and exposure over the 7 
time periods was assessed by the xtreg (cross-sectional time dependent 
regression) procedure. Stata 12 software, StataCorp, College Station, Texas, 
USA was used to carry out all analyses and results interpreted with the help 
of a statistician. 
The University of Cape Town Human Research Ethics Committee as well as 
the Department of Research Council approved this study. 
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RESULTS 
A total of 51 patients (34 male and 17 female) had sinonasal tumours 
endoscopically excised by the same surgeon at our institution from 2006 – 
2010 and met our inclusion criteria. There were 18 patients with malignant 
lesions and 33 patients with benign lesions (Figure 1). Mean patient age was 
51.1 years (range 13-78 years); this was normally distributed.  
Figure 1 : 



















5 Squamous Cell Ca
















In our series, 42 patients were planned to have curative surgery and 9 
patients had extensive tumours planned for palliative debulking and adjuvant 
treatment (Figure 2). 
Figure 2 : 
Curative Surgery (n=42)
Palliative Debulking (n=9)
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Patients reporting symptoms of nasal obstruction and nasal discharge 
together with clinical findings of nasal discharge/excessive crusting and a 
wide nasal cavity were used as criteria to label patients as having atrophic 
rhinitis. Biopsies of suspicious areas were taken and sent for microbiology 
and histopathological examination. No swabs were taken and the only 
medical treatment throughout the course was normal saline nasal douches 
and nasal hygiene. Potential recall bias was minimal as the symptoms 
patients’ reported and clinical signs seen by the same clinician were 
documented in the notes.  
It was evident that after the initial post - operative follow up, all patients 
reported symptoms of nasal obstruction and nasal discharge. There were 
also clinical signs of nasal discharge and crusting which were suggestive of 
atrophic rhinitis. These findings were also evident in the majority of patients 
at the 6 week follow up despite proper nasal hygiene.  
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However, we noticed a significant change in symptoms and signs at a turning 
point of 12 weeks (3 months) post – operatively, when taking certain 
variables into account. This is possibly due to the time taken for appropriate 
re-epithelialisation, but further studies need to be done to evaluate and verify 
this. 
The most striking difference would be the patients who had residual/recurrent 
sinonasal tumour (n=19) compared with those patients who had tumour 
completely resected (n=32). The incidence proportion (IP) for developing 
symptoms and signs suggestive of atrophic rhinitis in those with 
residual/recurrent tumour relative to those with complete resection of tumour 
at the turning point of 12 weeks was 78.9% and 3.1% respectively. This 
results in a relative risk (RR) of 25.3, 95 % confidence interval (CI) of 3.7 – 
179.6 at week 12. Comparing the IPs over time in these two groups resulted 
in an overall p-value < 0.001 suggesting that patients with residual/recurrent 
tumour develop symptoms and signs suggestive of atrophic rhinitis over time 
relative to those in whom the tumour was completely excised (Comparative 
Graphs 1 & 2/Table 1). 
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We investigated patients who had the inferior turbinate (IT) resected during 
surgery (n=38) and compared them to patients who had their IT preserved 
(n=13). The IP for developing symptoms and signs of atrophic rhinitis in 
those who had the IT resected relative to those who had the IT preserved at 
turning point 12 weeks was 31.6% and 30.8% respectively. This results in a 
RR of 1.0, 95 % CI 0.4 – 2.63 at week 12. Comparing the IPs over time in 
these 2 groups resulted in an overall p-value = 0.96 which is not statistically 
significant. Thus resecting the IT was not a factor in the development of 
atrophic rhinitis over time (Comparative Graphs 3 & 4/Table 1).  
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We also looked at the patients who had both inferior turbinate (IT) and middle 
turbinate (MT) resected (n=35) and compared them to patients who had the 
IT an MT preserved (n=10). The IP for developing symptoms and signs 
suggestive of atrophic rhinitis in those who had both IT and MT resected 
relative to those who had the IT and MT preserved at the turning point of 12 
weeks was 34.3% and 40.0% respectively. This results in a RR of 0.9, 95% 
CI of 0.5 – 3.6 at week 12. Comparing the IPs over time in these 2 groups 
resulted in an  overall p-value = 0.75 which is not statistically significant. 
Thus resecting the IT and MT did not influence the development of atrophic 
rhinitis over time (Comparative Graphs 5 & 6/Table 1).  
IP of Patients with Symptoms & Signs 
suggestive of AR
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A significant variable found was with patients who received adjuvant 
radiotherapy (n=17). We compared these patients with those who did not 
receive adjuvant radiotherapy (n=34). The IP for developing symptoms and 
signs suggestive of atrophic rhinitis in those who had adjuvant radiotherapy 
relative to those we did not receive adjuvant radiotherapy at the turning point 
of 12 weeks was 47.1% and 23.5% respectively. This results in a RR of 2.0, 
95% CI 0.9 – 4.4 at week 12. This seems not to be statistically significant at 
this point, but comparing the IPs over time in these two groups resulted in an 
overall p-value < 0.001 suggesting that patients who received adjuvant 
radiotherapy develop symptoms and signs suggestive of atrophic rhinitis over 
time relative to those who did not receive adjuvant radiotherapy. This is 
possibly due to the long term side effects radiotherapy has on tissues and 
bone resulting in mucosal damage, destruction of ciliary function, 
longstanding mucositis and radiogenic osteitis of the underlying bony 
structures. Again, further studies are needed to evaluate this.  (Comparative 
Graphs 7 & 8/Table 1). 
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Table 1:  Evaluation of relative risk of atrophic rhinitis (12 weeks post – op) 
and overall p-values  
Variable  N % AR at 
12 
weeks 



























 1.0 (0.4 
– 2.63)  
 
Resected 38 31.6 =0.96 
 









0.9 (0.5 – 
3.6) 
 
















No 17 47.1 <0.001 
 
      
Abbreviations: IT, inferior turbinate; MT, middle turbinate; AR, atrophic 
rhinitis; IP, incidence proportion 
 
Variables such as age, gender, bilateral disease and whether tumour was 
benign or malignant or extent of surgery was not statistically significant in the 












Over the past decade, there has been a natural evolution in the capabilities 
of endoscopic sinus surgeons. Advances in endoscopic instrumentation, 
along with intraoperative imaging, and increased experience with endoscopic 
repair of even large skull base defects, have opened up new and exciting 
possibilities. At the same time, many endoscopic surgeons have continued to 
fine-tune their skills and improve their knowledge of the complex orbital and 
skull base anatomy. Initially advocated for obstructive inflammatory disease, 
endoscopic approaches are now being used increasingly for the definitive 
treatment of nasal and paranasal sinus tumours, previously resected through 
more traditional (transfacial or craniofacial) approaches. Endoscopic 
management of benign lesions and even some malignant lesions, reflects a 
fundamental change from the more traditional therapeutic concepts and 
modalities.1-3 
Sinonasal tumours have been resected endoscopically at Groote Schuur 
Hospital in Cape Town South Africa since 2003. Almost all benign and 
intermediate tumours are removed endoscopically as well as malignant 
tumours amenable to this minimally invasive surgical approach. Surgery, 
although seen as minimally invasive because no external incisions are 
visible, is often very aggressive and destructive to the nasal structures.  
Current literature suggests that one of the causes of secondary atrophic 
rhinitis is overaggressive nasal surgery, particularly turbinate surgery.6-9  
If the theory regarding developing atrophic rhinitis after a simple turbinectomy 
stands true, one would expect all patients undergoing radical resection of the 
nasal structures to develop atrophic rhinitis. This has not been the case in 






Studies have examined the likely aetiology and diagnosis of secondary 
atrophic rhinitis (SAR). The largest study to date by Moore and colleagues 
(Mayo Clinic Otorhinolaryngology) published in 2001, identified 242 cases of 
atrophic rhinitis of which 197 cases were SAR. According to this study, 
24%(47) were due to complete removal of the lower and middle turbinates, 
56%(110) were due to partial removal of the lower and/or middle nasal 
turbinates, 10%(20) to endonasal sinus surgery without turbinectomy, 6%(12) 
tumour removal with partial maxillectomy, 2%(4) due to sinonasal irradiation 
and 2%(4) due to nasal trauma/granulomatous disease.4  
Some of the older studies done between1987 – 1999 have authors reporting 
15 – 89% of their own patients experiencing post - operative atrophic rhinitis 
symptoms after nasal tissue removal particularly in the form of turbinectomy. 
A retrospective study by Moore and colleagues published in 1985 (University 
of Nabraska) identified 18 patients who had undergone total inferior 
turbinectomies for nasal obstruction (1977 – 1982). They were followed up 
for three to five years and 16 of 18(89%) developed symptoms and signs of 
atrophic rhinitis.5  
Warwick – Brown and colleagues published another retrospective study in 
1987 where 24 out of 207 patients with nasal obstruction were found to have 
undergone partial inferior turbinectomy (Royal Berkshire Hospital, Reading 
UK). Follow up period was 16 years and 18 of 24(75%) developed atrophic 
rhinitis.6 In 1993 a publication by Salam and colleagues (Hull Royal Infirmary, 
Hull) showed in a prospective trial of 25 patients, that total inferior 
turbinectomy resulted in 4 of 25(16%) developing atrophic rhinitis after a 6 
month follow up period.7 Another prospective trial published in 1995 by 
Oburra (Aga Khan Hospital, Nairobi) revealed 5 of 34(15%) patients who had 
bilateral total inferior turbinectomies developed atrophic rhinitis.8 The follow 
up period was not stated in this study. One further prospective study 
published in 1999 by Passali and colleagues (Siena Medical School, Siena, 
Italy) confirmed atrophic rhinitis in 10 of 45(22%) of patients who had 
undergone total inferior turbinectomy  and followed up for 4 years.9  
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Other authors report that they have never encountered a case of atrophic 
rhinitis after total removal of the inferior turbinates. Martinez and colleagues 
(Nebraska University – Otorhinolaryngology), in 1983, found 29 patients who 
underwent total inferior turbinectomy for nasal obstruction. This was a 
prospective study and patients were followed for 2 – 60 months.10 Only 1 
patient developed excessive dryness but no atrophy. Odetoyinbo in 1987 
(Department of Surgery – Nigeria) reported that none of their 39 patients who 
underwent total inferior turbinectomy had developed atrophic rhinitis after a 2 
year follow up. This too was a prospective study.11 A retrospective study 
done by Courtiss and colleagues, (Division of Plastic surgery, Harvard 
Medical School) published in 1989, showed a 10-year follow up of patients 
who had total inferior turbinectomy with none developing symptoms of 
atrophic rhinitis.12 This study involved 25 patients age range from 24 to 74 
years (mean 39 years).  
A retrospective study published in 1989 by Ophir, (Kaplan Hospital – Israel) 
showed 38 patients who also underwent total inferior turbinectomy for nasal 
obstruction. There were no signs or symptoms of atrophic rhinitis post – 
operatively and the follow up was from 1 to 7 years.13  
The first prospective study involving resection of the middle turbinate for 
nasal obstruction was published in 1995 by Cook and colleagues (University 
of Missouri School of Medicine). This study looked at the effect of partial 
middle turbinectomy on nasal airflow and resistance. Thirty-one patients 
were included in the study and were followed up for 3 to 10 months post – 
operatively. No patients developed atrophic rhinitis and nasal function was 
enhanced.14 In 2000 Talmon and collegues (Western Gallilee Hospital – 
Israel) reported on 357 patients who underwent total inferior turbinectomy. 
This was a prospective study and patients were followed up for 6 years. No 
patient developed atrophic rhinitis.15 They also commented that even though 
the climate was hot, dry and dusty, no patients developed excessive dryness 
or atrophy.  
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Searching for studies reporting atrophic rhinitis as a result of endoscopic 
sinonasal tumour surgery, delivered no results. There are reports on the 
endoscopic management of sinonasal inverted papillomas but no studies 
mention atrophic rhinitis as a complication of the surgery. The studies were 
mainly concerned with tumour recurrence rates.3 
Two studies published in 2005 and 2008 respectively, compared endoscopic 
and open approaches for sinonasal tumour (benign and malignant) resection. 
Again no mention is made of atrophic rhinitis as a post-operative 
complication, with the main focus again being recurrence rates.1, 2  
Published literature evaluating the cause effect relationship of atrophic 
rhinitis as a result of nasal surgery is not clear. Also the incidence of atrophic 
rhinitis after endoscopic sinonasal tumour resection cannot be identified by 
an extensive literature review. This represents a significant gap both in the 
existing literature and in evidenced-based practice.  
To summarize, the literature is not clear with regards to nasal surgery as a 
possible causative factor in the development of atrophic rhinitis. No reports 
could be found on atrophic rhinitis as a result of endoscopic sinonasal tumour 
resection. This generates an interesting research question. Would the 
endoscopic resection of tumours lead to the development of atrophic rhinitis 
in patients where the normal nasal structures (such as the turbinates and 
septum) have been sacrificed? 
Certainly from our series of patients the surgery or extent of surgery did not 
significantly affect the development of atrophic rhinitis. We did however show 
that residual or recurrent disease and those who received adjuvant 
radiotherapy had a statistically significant chance of developing the 
symptoms and signs of atrophic rhinitis over time.  
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CONCLUSIONS 
Development of atrophic rhinitis is not more common in patients having 
endoscopic sinonasal surgery according to our study. However having 
residual or recurrent sinonasal disease and/or having adjuvant radiotherapy 
did have a statistically proven effect on the development of symptoms and 
signs of atrophic rhinitis over time. 
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 Smoking and  alcohol intake history
 Diabetic / Non-diabetic
 Other major medical co-morbidity (COPD, CCF, HTN, liver disease)
DISEASE-RELATED 
 Histological diagnosis
 Areas involved with tumour
PROCEDURE-RELATED 
 Extent of tumour resection
 Complications
 Repeat surgery
 Post op adjuvant treatment
POST-OPERATIVE FACTORS 
 Patient symptoms on each visit
 Clinical signs on each visit
 Strict follow up period
 Routine post - operative care and management
 Residual/recurrence of disease





ATROPHIC RHINITIS POST ENDOSCOPIC SINONASAL TUMOUR RESECTION STUDY




Sex: M / F
Smoking history: Current smoker / Ex – smoker / Lifetime non-smoker
Cigs / day:
Alcohol use: Teetotal / Ex-drinker / Drinker
(No. of units / week)
Diabetic: Y / N
Symptoms pre-op 
Signs pre-op





Curative surgery: Y   /   N
Repeat surgery: Y   /   N

















Adjuvant Treatment: Y   /   N
If yes, what treatment:
Residual/Recurrence: Y   /   N




Gender Age IP Mening Schwan OF FiDys Hemangio NasMass MalMel Esthesio AdenoCa SqCellCa NeuroEnd ChondroSarc Carcinoid Muco Benign
1 62 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 30 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1
0 50 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 48 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 66 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 24 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1
1 37 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 65 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 35 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 75 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1
0 65 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 46 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 52 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 42 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1
1 63 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 59 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 66 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 13 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1
0 70 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 23 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 48 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 62 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1
0 33 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 13 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1
1 38 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 44 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 30 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 13 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1
1 59 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 28 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1
1 44 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 68 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
1 45 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
0 70 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
0 76 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
1 48 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
1 47 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
0 75 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
1 19 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 56 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
1 72 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 76 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
1 51 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
1 49 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
1 54 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
0 64 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
1 68 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
0 57 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
1 78 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
1 70 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
1 63 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
Right Left Bilateral IT MT Latwall Sept Ft Et Sph Crib Intraorb Intracran Ittk Mttk MM Septtk Ftk Etk Sphtk Cribtk
0 1 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 1 1 0
0 0 1 1 0 0 1 0 0 0 0 0 0 1 0 0 1 0 0 0 0
1 0 0 1 0 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0
1 0 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
0 0 1 1 1 1 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0
0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
0 1 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0
0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
1 0 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 1 1 1 0 0 0 1 1 1 0 1 1 1 0
0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 1 0 0 1 1 0 1 1 1 1 1 0 0 1 0
0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
0 1 0 1 1 1 0 1 0 1 0 0 0 1 1 1 0 1 1 1 0
1 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 1 0
0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
0 1 0 1 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 0 0 1 1 1 0 1 1 1 1 0 1 1 1 0
0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 0 1
0 0 1 0 0 0 1 1 1 1 1 0 0 0 0 0 1 0 0 0 1
0 1 0 0 0 0 1 0 0 1 0 0 0 0 1 0 1 0 0 1 0
0 0 1 0 0 0 1 0 0 1 1 0 0 0 0 0 1 0 0 0 1
0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0
1 0 0 1 1 1 1 0 0 1 0 0 1 1 1 1 1 0 0 1 0
1 0 0 1 1 1 1 1 0 0 1 0 0 1 1 1 1 1 0 0 1
0 0 1 0 0 0 0 0 0 1 1 1 1 0 0 0 1 0 0 0 1
0 0 1 0 0 0 1 0 0 0 1 1 1 0 0 0 1 0 0 0 1
0 0 1 0 0 0 1 0 0 1 0 0 0 0 0 0 1 0 1 1 0
0 1 0 0 0 0 1 1 1 0 0 0 0 0 1 0 1 1 1 1 0
1 0 0 1 1 1 0 1 0 0 1 1 1 1 1 1 0 1 1 1 0
0 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 1 0
0 1 0 0 1 0 0 0 1 1 0 0 0 1 1 1 0 1 1 1 0
0 0 1 0 0 0 1 0 0 1 1 0 0 0 0 0 1 0 0 1 0
0 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 1 0
0 0 1 0 0 0 1 1 1 1 1 0 0 0 1 0 1 1 1 1 0
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1 1 1 1 1 1 1 1 1 1 1 1 0 0
1 1 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 0 0 0 0 0 0 0 0 0 0 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 0 1 0 0 0 0 0 0 0 0 0 0
1 1 0 1 0 0 0 0 0 0 0 0 0 0
1 1 0 1 1 1 1 1 1 1 1 1 0 0
1 1 0 0 0 0 0 0 0 0 0 0 0 0
1 1 1 1 0 0 0 0 0 0 0 0 0 0
1 1 1 1 0 0 0 0 0 0 0 0 0 0
1 1 1 1 0 0 1 1 1 1 1 1 0 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 0 0 0 0 0 0 0 0 0 0
1 1 1 1 0 0 0 0 0 0 0 0 0 0
1 1 1 1 0 0 0 0 0 0 0 0 0 0
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RadioRx ChemoRx Residual/Recurrence Histologically confirmed Repeat surgery Maj Complications
0 0 1 1 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 1 0 0
0 0 0 0 0
0 0 0 0 0
0 0 1 1 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 1 1 0
0 0 1 1 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 1 1 0
0 0 0 0 0 Key 
0 0 0 0 0 1 = yes
0 0 0 0 0 0 = no
0 0 0 0 0 Red = Different tumour types
0 0 0 0 0 Green= Areas involved with tumour
0 0 0 0 0 Light blue = Structures excised during surgery
0 0 0 0 0 Purple = Patient symptoms
0 0 0 0 0 symNO = Nasal obstruction
0 0 0 0 0 symND = Nasal discharge
0 0 1 1 0 Orange = Clinical Signs
0 0 0 0 0 siND = Nasal discharge
0 0 0 0 0 siNC = Nasal crusts
1 0 1 0 0 siNcav = sign Normal cavity
0 0 0 0 0 Gender
1 0 0 0 0 1 = Male
1 0 1 0 0 0 = Female
1 1 0 0 0
1 1 1 1 0
0 0 0 0 0
0 0 1 1 0
1 0 1 0 0
1 1 1 0 0
1 0 1 1 0
1 0 0 0 0
1 1 1 0 0
0 0 0 0 0
1 0 0 0 0
1 0 1 0 0
1 0 1 0 0
1 0 0 0 0
1 0 0 0 0
1 0 1 0 0
1 0 0 0 0
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APPENDIX II:  ENDOSCOPIC PICTURES 
Complete Tumour Resection
2 years Post-op 
Inverted Papilloma
Complete Tumour Resection













APPENDIX III:  
HUMAN RESEARCH ETHICS COMMITTEE APPROVAL 
signature removed
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APPENDIX IV:  
DEPARTMENTAL RESEARCH ETHICS COMMITTEE APPROVAL 
signature removed
53 
APPENDIX V:  AUTHOR GUIDELINES: RHINOLOGY
Submission 
Please go to our website at 'www.rhinologyjournal.com/review/' to submit your article. If this is 
your first manuscript, a new user account should be made where you will make a username 
and password. Before you prepare your manuscript, download the template at 
'www.rhinologyjournal.com/review/' to submit your article. If this is your first manuscript, a 
new user account should be made where you will make a username and password. Before you 
prepare your manuscript, download the template and use that as a starting point for your 
manuscript. If you already had prepared your paper, please use 'copy - paste special - 
unformatted text' to enter your text in the template. In the submission module you can enter 
your new manuscript by filling out the required fields and upload your manuscript. Please 
prepare a complete manuscript in the Word template and save it in .doc(x) or .rtf format. 
Upload all figures and tables in separate files. Further instructions are available on the 
template.  
The manuscript
Manuscripts should be complete in all respects. The manuscript should be typed in double 
spacing on one side only of A4 paper (21x27.9 cm) with ample (2.5 cm) top and left-hand 
margins. Figures and Tables should be referred to in consecutive order as 'Figure 1', etc. and 
'Table 1', etc 
Original papers should be divided into sections: Summary, Key words, Introduction, Materials 
and Methods, Results, Discussion, Acknowledgements, References, Tables, Legends for 
illustrations, and Legends for tables. After the last reference, the title and name, and full postal 
address of the corresponding author should be typed. Begin each section and Figure and Table 
legends on separate sheets, and type the page number in the upper right-hand corner of each 
page. 
The front page of the manuscript should contain: 
(1) title of the manuscript (not exceeding 100 characters including spaces);
(2) name of author(s);
(3) name of department(s), institution(s) and/or laboratories;
(4) full postal address of the author to whom reprints are to be requested (please include
telephone and/or telefax numbers and e-mail address);
(5) running title not exceeding 30 characters including space;
(6) five key words for indexing purposes using MeSH terms.
Summary 
Every paper should include a factual summary of its contents. It should be intelligible in itself 
without reference to the paper, and not exceed 200 words. It must include statement of 
problem, method(s) of study, main results (only words, no statistics), and principal 
conclusions. Footnotes and references are not used in the summary.  
Keywords 
Use comma's to separate the different keywords. Use meshwords as indicated in Pubmed 
References 
Citations in the text should be referred to using the Vancouver system in which a number is 
assigned to each reference as it is used. This should appear in superscript inside the text 
punctuation. Even if the author(s) is named, a number must still be used. 
- The full reference must be listed in numerical order at the end of the paper in the
bibliography.
- The original number assigned to the reference is used each time the reference is cited in the
text, regardless of its position in the text.
The titles of journals should be abbreviated according to the style used in Index Medicus 
(Medline). A list of abbreviated names of frequently cited journals is printed annually in the 
January issue of Index Medicus. They can also be found listed at the US National Library of 
Medicine Website at http://www.nlm.nih.gov/tsd/serials/lsiou.html. 
Use the style of the examples below, which are based on the formats used by the National 
Library of Medicine. When you use Endnote or Reference Manager, remove all embedded links 
in the final document to prevent incompatibilities with Editorial software. 
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References should be according to the following examples: 
Extract from Adams JC, Hamblen DL. Outline of fractures. 10th ed. Edinburgh: Churchill 
Livingstone, 1992: 
In younger patients operative repair is advised. It entails exposure of the tendon from above 
by splitting the acromion in the coronal plane, and reattachment of the tendon by sutures 
through drill holes in the tuberosity of the humerus (1,2). Thereafter a long course of 
supervised exercises may be required before a full range of active movement is restored. As 
would be expected, the results of operation tend to be poorer in cases of large musculo-
teninous defects than when the rent is small (2). 
- Debeyre J, Patte D, Elmelik E. Repair of ruptures of the rotator cuff of the shoulder. J Bone
Joint Surg Br. 1965; 47B: 36-42.
- Kessel L, Bayley I. Clinical disorders of the shoulder. 2nd ed. Edinburgh: Churchill
Livingstone, 1986.
Journal 
- An article in a journal: (List all authors when six or less; when seven or more, list only first
three and add et al).?You CH, Lee KY, Chey WY, Menguy R. Electrogastrographic study of
patients with unexplained nausea, bloating and vomiting. Gastroenterology 1980; 79: 311-
314.
- A corporate author: The Royal Marsden Hospital Bone-Marrow Transplantation Team. Failure
of syngeneic bone-marrow graft without preconditioning in post-hepatitis marrow aplasia.
Lancet 1977; 2: 242-244.
- No author given: Anonymous. Coffee drinking and cancer of the pancreas (Editorial). Br Med
J 1981; 283: 628.
Books and other monographs 
- Personal author(s):
Eisen HN. Immunology: an introduction to molecular and cellular principles of the immune
response. 5th ed. New York: Harper and Row, 1974
- Editor, compiler, chairman as author:
Dausset J, Colombani J, eds. Histocompatibility testing 1972. Copenhagen: Munksgaard, 1973:
12-18.
- A chapter in a book:
Weinstein L, Swartz MN. Pathogenic properties of invading micro-organisms. In: Sodeman WA
Jr, Sodeman WA, eds. Pathologic physiology: mechanisms of disease. Philadelphia: WB
Saunders, 1974; 457-472.
Illustrations 
Always submit high-resolution figures (300 dpi) that meet the following specifications: 
File Sizes: Figure files should not exceed 10 MB (average size is about 2 MB). 
Image Sizes: Figures should be submitted in final print publication size (printed 1:1). Figures 
may be published in print in one of two formats: single-column (8.5 cm) or double-column 
(18.0 cm). Unless the file size is too large, multi-panel figures should be submitted as a single 
file. 
Text and Lines: Text in figures must be 6-8 points in size, except for single letter markers, 
which must be 12 points. Myriad Pro should be used for all figure text (except for the use of 
symbols). Line widths must be greater than one point thick or they will not appear on the PDF 
version of the article. 
Numbering: Figures must be numbered as they appear in the text. 
File Format: Original figures should be in TIFF (better for halftone art e.g., blots, photographs), 
or EPS (better for line art or monochrome art, i.e., anything that involves sharply delineated 
lines). Figures can be submitted in powerpoint with page setup at A4 size.  
The editors will determine the degree of any reduction or enlargement required and, in 
general, line drawings will be reduced to one column width if possible. Authors may, however, 
specifically request a larger reprodution. Particular requests should be typed on the relevant 
figure legend page. Photomicrographs will usually not be reduced unless the reduction involved 
is small or the height necessitates reduction. 
Colour: Colour figures must be in the RGB color space. Colour printing is available subject to 
authors meeting the costs involved. We charge € 250.- per page with a maximum of € 500,-. 
When colour figures have been submitted, it is assumed by the editorial staff the figures will 
have to be printed in colour and an invoice will be send.  
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Tables 
Tables should be typed using the table function in Word or Pages, the required number of cells 
should be chosen, double spaced, and should contain only horizontal lines. Each table is on a 
separate page, numbered consecutively with Arabic numerals 'Table 1', etc. 
If a manuscript does not fullfill these requirements, it will be returned to the authors. 
Case Reports 
As from April 1, 2009, the journal does NOT accept anymore Case reports. 
Proofs 
PDF proofs will be sent by e-mail to the first-named author of the paper, unless an alternative 
is requested on the title page of the manuscript. They should be checked carefully and 
returned by fax or e-mail within 7 days to the Managing Editor. If the proofs are not received in 
time, the author is considered to rely on the Editor's correction only. Corrections must be 
clearly indicated. The author is responsible for mistakes that have been overlooked. Changes 
or additions to the edited manuscripts, other than correcting printer's errors, are not allowed at 
this stage.  
Reprints 
Reprints may be ordered by filling in and returning to the Managing Editor the order form sent 
to the corresponding author with the proof.pdf. A pdf file per contribution will be provided, free 
of charge.  
Editorial policy 
While papers are subject to peer review and editing, the journal does not hold itself responsible 
for all statements made by contributors.  
The Editors reserve the right to refuse any manuscript submitted and to make suggestions for 
modifications before publication. Manuscripts are submitted to referees for peer review. The 
authors will receive a confirmation of the arrival of their manuscripts. They will generally be 
notified of the editorial decision within two months. In case a manuscript is returned to the 
author for revision, it should be resubmitted through the website within 6 months. Papers 
accepted by the Editorial Board are scheduled for publication in chronological order of 
submission as much as possible. Every effort will be made to achieve rapid publication on our 
website as well as in print. This will be facilitated if authors provide good and complete copy by 
following these instructions.  
Disclaimers 
While papers are subject to peer review and editing, statements and opinions expressed in 
articles and communications hererin are those of the author(s) and not necessary those of the 
Editor(s), publisher or the European Rhinologic Society of the International Rhinologic Society. 
The Editor(s), publisher the European Rhinologic Society and the International Rhinologic 
Society disclaims any responsibility of liability for such material and do not guarantee, warrant, 
or endorse any product or service in this publication, nor do they guarantee any claim made by 
the manufacturer of such product or service.  
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TEMPLATE: 
THANK YOU FOR DOWNLOADING THIS FILE AND USE OF THIS TEMPLATE TO PREPARE
YOUR MANUSCRIPT FOR SUBMISSION TO RHINOLOGY. WE REQUEST A DEGREE OF
CONFORMITY BECAUSE DUE TO THE EVER INCREASING NUMBER OF PAPERS BEING 
SUBMITTED, WE NEED TO FACILITATE THE PRESENTATION TO ASSIST THE REVIEWING
AND PUBLICATION PROCESS FOR THE BENEFIT OF OUR READERS. 
• USING THIS TEMPLATE (ARTICLE – GENERAL)
The template consists of essential headings along with body text explaining what to 
include in each section. You should overwrite (or copy and paste (paste special – 
unformatted text)) the body text with the corresponding section text for your article. 
Obviously, you should add other headings as needed, and delete the examples and 
unnecessary text. Please adhere to the font size and type. Finally, please use British 
English spelling, eg: tumour, colour, analyse 
Running title:  
Provide a short comprehensive title of no more than 50 characters eg.: 
RCT Rapid Rhino versus Netcell 
TYPE OF ARTICLE 
Categorize your article in one of the following types: 
REVIEW / MINI REVIEW / ORIGINAL CONTRIBUTION / SPECIAL REPORT / 
OTHER 
Title 
The title (font 14) should be specific to the study yet concise, and should allow 
sensitive and specific electronic retrieval of the article. It should be comprehensible to 
readers outside your field. Avoid specialist abbreviations if possible. Present this in 
Sentence case, capitalizing only the first word or names, and abbreviations, e.g.: A 
randomised controlled trial comparing Rapid Rhino Mannheim and Netcell series 
5000 packs following routine nasal surgery. 
Authors 
Provide the first names or initials (if used), middle names or initials (if used), 
surnames, and affiliations (use numbers in superscript when more departments have been involved). Do not 
add any degrees eg. MD, PhD.  Eg: Valerie J. Lund1 or W.J. Fokkens2
Affiliation 
Department, university or organization, city, state/province (if applicable), and country - for all authors. 
From here, the paper should be written with spacing of lines at 1,5. 
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SUMMARY 
The abstract succinctly introduces the paper. We advise that it should not exceed 200 
words. The abstract is conceptually divided into three or four sections.  
Background: include here a statement of the main research question. 
Methodology/Principal: include here the techniques used without going into 
methodological detail  
Results: give a summary of the most important findings with key numerical results 
given, with measures of error and not just p values.  
Conclusions: concisely summarize the study’s implications. Please do not include any 
citations in the abstract. Avoid specialist abbreviations if possible 
Key words: Provide up to 5 key words using Mesh terms for indexing purposes 
INTRODUCTION 
The introduction should put the focus of the manuscript into a broader context. As you 
compose the introduction, think of readers who are not experts in this field. Include a 
brief review of the key literature. If there are relevant controversies or disagreements 
in the field, they should be mentioned so that a non-expert reader can delve into these 
issues further (1). The introduction should conclude with a brief statement of the overall 
aim of the experiments and a comment about whether that aim was achieved. 
(1) Citations should be included in order of appearance with numbers between
(parenthesis) and in superscript.
MATERIALS AND METHODS
This section should provide enough detail to allow full replication of the study by
suitably skilled investigators. Protocols for new methods should be included, but well-
established protocols may simply be referenced. If applicable, info on ethics approval
of either human or animal ethical committees should be stated here.
Various headings should be provided in italics: eg patients, surgery, ELISA, statistical
analysis
RESULTS
The results section should provide details of all of the experiments that are required to
support the conclusions of the paper. There should be a brief introduction of each
section and end with a summarizing sentence of the main finding of the experiment
without discussion. There is no specific word limit for this section. The section may
be divided into subsections, each with a concise subheading (in italics).
Large datasets, including raw data, could be submitted as supporting information files;
these are published online alongside the accepted article. We advise that the results
section be written in past tense.
DISCUSSION
The discussion should spell out the major conclusions of the work along with some
explanation or speculation on the significance of these conclusions. How do the
conclusions affect the existing assumptions and models in the field? How can future
research build on these observations? What are the key experiments that must be done?
The discussion should be concise and tightly argued. Conclusions firmly established
by the presented data, hypotheses supported by the presented data, and speculations
suggested by the presented data should be clearly identified as such. No more new data
should be presented in the discussion.
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